Table 3.
Mixed-model meta-regression analysis of potential moderators of difference in brachial artery endothelium-dependent flow-mediated dilation.
| Regression coefficient (SE) | z-score | df | p-value | |
|---|---|---|---|---|
| Age, year | 0.004459(0.03261) | 1.36791 | 24 | 0.172 |
| Female,% | 0.04538(2.70484) | 0.01678 | 24 | 0.987 |
| DM, % | −15.81709(7.98021) | −1.98204 | 19 | 0.047 |
| HT, % | −0.46715(1.74889) | −0.26711 | 16 | 0.789 |
| Smoking, % | 0.59631(1.17388) | 0.50798 | 15 | 0.611 |
| Menopause, % | 1.48237(1.01263) | 1.46388 | 9 | 0.143 |
| BMI, kg/m2 | 0.16425(0.15941) | 1.03039 | 18 | 0.303 |
| SBP, mmHg | −0.02230(0.02256) | −0.98834 | 16 | 0.323 |
| DBP, mmHg | −0.04573(0.02272) | −2.01229 | 15 | 0.044 |
| TC, mg/dL | −0.00495(0.00874) | −0.56697 | 20 | 0.571 |
| HDL, mg/dL | 0.01665(0.02836) | 0.58723 | 18 | 0.557 |
| LDL, mg/dL | 0.00796(0.01714) | 0.46419 | 16 | 0.643 |
| TG, mg/dL | −0.00188(0.00909) | −0.20739 | 16 | 0.836 |
| ESR, mm/hr | −0.08544(0.04023) | −2.12382 | 6 | 0.034 |
| CRP, U/L | −0.00351(0.07112) | −0.04930 | 12 | 0.961 |
| SLEDAI, unit | −0.07136(0.05891) | −1.21141 | 15 | 0.226 |
| Renal involvement, % | −4.89258(2.21542) | −2.20843 | 10 | 0.027 |
| Prednisolone use, % | −0.32784(1.26973) | −0.25820 | 17 | 0.796 |
| Mean prednisolone dose, mg/day | −0.07484(0.06059) | −1.23531 | 12 | 0.217 |
| HCQ use, % | −1.10975(1.48537) | −0.74712 | 17 | 0.455 |
| Aspirin use, % | −2.17895(0.67208) | −3.24208 | 6 | 0.001 |
| ACA positivity, % | −0.08995(2.4885) | −0.03688 | 12 | 0.971 |
| APASx, % | −2.47656(3.01813) | −0.82056 | 4 | 0.412 |
| Disease durations, months | 0.00510(0.0382) | 1.33454 | 16 | 0.182 |
Abbreviations: SE, standard error; df, degree of freedom; DM, diabetes mellitus; HT, hypertension; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure;TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; TG, total triglyceride; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; HCQ, hydroxychloroquine; ACA, anti-cardiolipin antibodies; APASx, antiphospholipid antibody syndrome.